Syros Pharmaceuticals Closes $53M Series B Funding

syros_LogoSyros Pharmaceuticals, a Watertown, MA-based therapeutics company focused on discovering and developing novel gene control therapies in cancer and other diseases, closed a $53m Series B funding.

The round was led by a large, Boston-based public investment firm, with participation from new investors Polaris Partners, Aisling Capital and Redmile Group and current investors Flagship Ventures, ARCH Venture Partners, WuXi PharmaTech Corporate Venture Fund and Alexandria Venture Investments.

The company intends to use the funds to advance its portfolio of cancer programs towards the clinic and to expand its gene control product engine into new therapeutic areas.

Launched in 2013 and led by Nancy Simonian, M.D., Chief Executive Officer, Syros Pharmaceuticals leverages its proprietary platform that maps gene control pathways directly in human disease tissue to identify and modulate the gene switches important in disease, and patients most likely to benefit from its gene control medicines.



Join the discussion